Subject Characteristics, Pretreatment, and 11C-4DST PET Protocol and Data
| Protocol | Data | |||||||||
| Subject no. | Age (y) | Sex | Diagnosis | Pretreatment | Region | Dose (MBq/nmol) | Duration (min) | Mean SUV | Maximal SUV | Ki (min−1) |
| 1 | 42 | M | Oligo (grade 3) | Op/XRT (55 Gy)/TMZ | Brain | 528/1.7 | 45 | 2.2 | 3.3 | 0.047 |
| C/L brain | 0.5 | 1.0 | 0.010 | |||||||
| 2 | 48 | M | As (grade 3) | XRT (60 Gy)/TMZ/GK | Brain | 745/10.0 | 60 | 0.8 | 1.6 | —* |
| C/L brain | 0.3 | 0.8 | —* | |||||||
| 3 | 56 | M | As (grade 3) | Op/GK/TMZ | Brain | 749/2.5 | 90 | 0.9 | 1.2 | 0.017 |
| C/L brain | 0.3 | 0.6 | 0.007 | |||||||
| 4 | 44 | M | As (grade 3) | — | Brain | 731/3.8 | 90 | 1.3 | 2.3 | 0.025 |
| C/L brain | 0.6 | 1.5 | 0.011 | |||||||
| 5 | 46 | F | Lym | — | Brain | 727/5.9 | 40 | 1.2 | 2.4 | 0.044 |
| C/L brain | 0.5 | 1.0 | 0.015 | |||||||
| 6 | 50 | F | Met (from LK) | Op/GK (×3) | Brain | 817/1.9 | 60 | 2.1 | 5.1 | 0.046 |
| C/L brain | 0.5 | 0.8 | 0.010 | |||||||
| 7 | 21 | M | Normal | — | Whole body | 655/11.4 | 120 | — | — | |
| 8 | 21 | M | Normal | — | Whole body | 743/9.5 | 120 | — | — | |
| 9 | 21 | M | Normal | — | Whole body | 666/7.7 | 120 | — | — | |
↵* Ki calculation was excluded because of failure of arterial blood sampling.
Oligo = oligodendroglioma; op = surgical operation; TMZ = temozolomide; C/L brain = contralateral normal brain; as =astrocytoma; XRT = external-beam radiotherapy; GK = γ-knife surgery; lym = malignant lymphoma; met = metastasis; LK = lung carcinoma.
Mean SUV was for 45 to 60 min after injection of 11C-4DST, except in subjects 1 (30−45 min) and 5 (30−40 min).